[go: up one dir, main page]

AR107488A1 - Compuestos de benzopirazol y análogos de éstos - Google Patents

Compuestos de benzopirazol y análogos de éstos

Info

Publication number
AR107488A1
AR107488A1 ARP170100240A ARP170100240A AR107488A1 AR 107488 A1 AR107488 A1 AR 107488A1 AR P170100240 A ARP170100240 A AR P170100240A AR P170100240 A ARP170100240 A AR P170100240A AR 107488 A1 AR107488 A1 AR 107488A1
Authority
AR
Argentina
Prior art keywords
alkyl
heterocycloalkyl
cycloalkyl
optionally substituted
6alkyl
Prior art date
Application number
ARP170100240A
Other languages
English (en)
Inventor
Krishnan Raman
Venkat R Chintareddy
Minwan Wu
Lakshminarayana Vogeti
Weihe Zhang
Yarlagadda S Babu
Pravin L Kotian
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of AR107488A1 publication Critical patent/AR107488A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)

Abstract

Se describen compuestos y sales de estos aceptables desde el punto de vista farmacéutico. Los compuestos son inhibidores del sistema de complemento. También se proporcionan composiciones farmacéuticas que comprenden un compuesto, y métodos que incluyen el uso de compuestos y composiciones en el tratamiento y prevención de enfermedades y afecciones caracterizadas por la actividad anómala del sistema de complemento. Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal de este aceptable desde el punto de vista farmacéutico, en donde, independientemente para cada caso: R¹ representa arilo, heteroarilo, cicloalquilo, heterocicloalquilo, alquilo, o alquenilo opcionalmente sustituidos; R² y R³ cada uno representa independientemente H, F, o alquilo, alquenilo, alquinilo, alcoxialquilo, haloalquilo, hidroxialquilo, (alquiltio)alquilo, aralquilo, heteroaralquilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, o (heterocicloalquil)alquilo opcionalmente sustituidos; o R² y R³, junto con el átomo de carbono al que están unidos, forman un anillo de cicloalquilo o heterocicloalquilo opcionalmente sustituido; R⁴ representa H o alquilo, alquenilo, alquinilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, (heterocicloalquil)alquilo, aralquilo, heteroaralquilo, hidroxialquilo, o haloalquilo opcionalmente sustituidos; X representa NH, CH₂, CHF, CF₂, CHC₁₋₆alquilo, o C(C₁₋₆alquilo)₂; Y está ausente o representa CH₂, C(O), CR¹⁵R¹⁶, S(O)₂, o C₃₋₇cicloalquileno, arileno o heteroarileno opcionalmente sustituidos; Rᵃ representa H o C₁₋₆alquilo, (heterocicloalquil)alquilo o C₃₋₇cicloalquilo opcionalmente sustituidos; m es un entero de 1 - 6; n es 0 ó 1; R¹⁵ y R¹⁶ se seleccionan independientemente del grupo que consiste en H, hidroxi, halógeno, -C(O)OR¹⁷, -OR¹⁷, -C(O)NR¹⁷R¹⁸, -NR¹⁷R¹⁸, alquilo, hidroxialquilo, haloalquilo, alcoxialquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, y (heterocicloalquil)alquilo, en donde alquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, y (heterocicloalquil)alquilo se sustituyen opcionalmente con uno o más sustituyentes seleccionados del grupo que consiste en -CN, -OR¹⁷, -NR¹⁷R¹⁸, halo, y alquilo; o R¹⁵ y R¹⁶, junto con el átomo interviniente, pueden formar un anillo carbocíclico o heterocíclico opcionalmente sustituido; R¹⁷ y R¹⁸ se seleccionan independientemente del grupo que consiste en H, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, arilo, aralquilo, heteroarilo, heteroaralquilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, y (heterocicloalquil)alquilo; o R¹⁷ y R¹⁸, cuando están unidos al mismo átomo, pueden formar, junto con el átomo interviniente, un anillo heterocíclico opcionalmente sustituido; el Anillo B representa un compuesto de fórmula (2), (3), (4), (5) ó (6); Z¹ y Z³ cada uno representa independientemente C o N; Z² representa N, CH, o CF; Z⁴ representa N o CR⁸; Z⁵ representa N o CR⁵; Z⁶ representa N o CR⁶; Z⁷ representa N o CR⁹; Z⁸ y Z⁹ cada uno representa independientemente N o CR¹⁹; R⁵ y R⁶ cada uno representa independientemente H, halógeno, -CN, -NO₂, -OR¹³, -NR¹³R¹⁴, -C(O)R¹³, -C(O)OR¹³, -C(O)NR¹³R¹⁴, -OC(O)R¹³, -NR¹³C(O)R¹⁴, -OC(O)NR¹³R¹⁴, -OC(O)OR¹³, -NR¹³C(O)OR¹⁴, -NR¹³C(O)NR¹³R¹⁴, -OS(O)ₚ(R¹³), -NR¹³S(O)ₚ(R¹⁴), o alquilo, alquenilo, alquinilo, haloalquilo, aralquilo, heteroaralquilo, heteroarilo, arilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, o (heterocicloalquil)alquilo opcionalmente sustituidos; L representa -H, -CN, -C(O)R⁷, -CH(OH)R⁷, o -S(O)ₚ(alquilo); R⁷, independientemente para cada caso, representa H, NH₂, CH₃, OH, CF₃, CH₂OH, C₁₋₆alquilo, hidroxi-C₁₋₆alquilo, C₁₋₆alcoxi-C₁₋₆alquilo, halo-C₁₋₆alquilo, NHC₁₋₆alquilo, N(C₁₋₆alquilo)₂; R⁸ y R⁹ cada uno representa independientemente H, halógeno, -OR¹³, -NR¹³R¹⁴, -C(O)R¹³, -C(O)OR¹³, -C(O)NR¹³R¹⁴, -OC(O)R¹³, -NR¹³C(O)R¹⁴, -OC(O)NR¹³R¹⁴, -OC(O)OR¹³, -NR¹³C(O)OR¹⁴, -NR¹³C(O)NR¹³R¹⁴, -OS(O)ₚ(R¹³), -NR¹³S(O)ₚ(R¹⁴), o alquilo, alquenilo, alquinilo, haloalquilo, aralquilo, heteroaralquilo, heteroarilo o arilo opcionalmente sustituidos; o R⁵ y R⁸ o R⁵ y R⁶, o R⁶ y R⁹, junto con los átomos intervinientes, pueden formar un anillo heterocíclico o carbocíclico opcionalmente sustituido; R¹³ y R¹⁴, independientemente para cada caso, representan H o alquilo, alquenilo, alquinilo, arilo, aralquilo, heteroarilo, heteroaralquilo, cicloalquilo, (cicloalquil)alquilo, heterocicloalquilo, o (heterocicloalquil)alquilo opcionalmente sustituidos; o cuando R¹³ y R¹⁴ están unidos al mismo átomo, R¹³ y R¹⁴, junto con el átomo, pueden formar un anillo heterocíclico opcionalmente sustituido; R¹⁹, independientemente para cada caso, representa H, F, CN, -C(O)R⁷, -CH(OH)R⁷, o -S(O)ₚ(alquilo); J representa H o NH₂; y p es 0, 1 ó 2; en donde, si Z¹ es N, o si el Anillo B representa el compuesto de fórmula (3), (4), (5) ó (6), entonces X representa CH₂.
ARP170100240A 2016-02-01 2017-01-30 Compuestos de benzopirazol y análogos de éstos AR107488A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662289653P 2016-02-01 2016-02-01

Publications (1)

Publication Number Publication Date
AR107488A1 true AR107488A1 (es) 2018-05-02

Family

ID=59500923

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100240A AR107488A1 (es) 2016-02-01 2017-01-30 Compuestos de benzopirazol y análogos de éstos

Country Status (30)

Country Link
US (3) US10849883B2 (es)
EP (2) EP3411411B3 (es)
JP (2) JP6924766B2 (es)
KR (1) KR102828456B1 (es)
CN (2) CN115490751A (es)
AR (1) AR107488A1 (es)
AU (1) AU2017213768B2 (es)
CA (1) CA3011549A1 (es)
CO (1) CO2018008916A2 (es)
CY (1) CY1124652T1 (es)
DK (1) DK3411411T6 (es)
EA (1) EA039719B1 (es)
ES (2) ES2982426T3 (es)
HR (1) HRP20210926T4 (es)
HU (1) HUE055258T2 (es)
IL (2) IL290154B2 (es)
LT (1) LT3411411T (es)
MA (1) MA43979B1 (es)
MD (1) MD3411411T2 (es)
MX (2) MX2018008869A (es)
MY (1) MY201629A (es)
PH (1) PH12018501537B1 (es)
PL (1) PL3411411T6 (es)
PT (1) PT3411411T (es)
RS (1) RS62187B2 (es)
SG (2) SG10202108797UA (es)
SI (1) SI3411411T1 (es)
SM (1) SMT202100494T1 (es)
TW (2) TWI854164B (es)
WO (1) WO2017136395A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
TWI854164B (zh) * 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
TWI873092B (zh) * 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2020132045A1 (en) 2018-12-19 2020-06-25 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
BR112021018456A2 (pt) 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
UY38909A (es) * 2019-10-09 2021-05-31 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
AR120173A1 (es) * 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
CN113512025B (zh) * 2020-07-31 2023-01-06 四川大学 一种吲唑酯类化合物及其制药用途
WO2025080823A1 (en) 2023-10-11 2025-04-17 Regeneron Pharmaceuticals, Inc. Treatment of macular degeneration with complement factor d (cfd) inhibitors
CN119638611B (zh) * 2024-12-08 2025-10-31 胥江生物科技(苏州)有限公司 N-乙酰-5-羟色胺衍生物、免疫原、抗体及检测试剂制备与应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
JPH05502179A (ja) 1990-02-28 1993-04-22 メドトロニック　インコーポレーテッド 管状器官内薬剤溶出装具
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
FI963272L (fi) 1994-02-22 1996-08-21 Merrell Pharma Inc Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
JP2002514180A (ja) * 1996-09-04 2002-05-14 ワーナー―ランバート・コンパニー マトリックスメタロプロテイナーゼを阻害するための化合物およびその方法
KR20000035992A (ko) 1996-09-10 2000-06-26 메디녹스, 인크. 폴리디티오카르바메이트 함유 거대분자 및 치료 및 진단을 위한
US6596770B2 (en) 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
DE60303441T2 (de) * 2002-02-08 2006-09-21 Merck & Co., Inc. N-biphenylmethylaminocycloalkancarboxamid-derivative
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
EP1433778A1 (en) * 2002-12-23 2004-06-30 Jerini AG Use of nitriles as rotamase inhibitors
US7335644B2 (en) * 2003-03-31 2008-02-26 Council Of Scientific And Industrial Research Anti-hypertensive molecules and process for preparation thereof
JP2007008914A (ja) * 2004-10-27 2007-01-18 Nissan Chem Ind Ltd 置換ジアミン化合物および農園芸用殺菌剤
WO2007115231A2 (en) * 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
CA2740783A1 (en) * 2008-10-17 2010-04-22 Exelixis, Inc. Sphingosine-1-phosphate receptor antagonists
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CN102464654B (zh) * 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
BR112013017316A2 (pt) * 2011-01-04 2019-09-24 Novartis Ag compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
WO2012166706A2 (en) * 2011-05-31 2012-12-06 Brandeis University Supramolecular nanofibers and hydrogels based on oligopeptides functionalized with nucleobases
US10093674B2 (en) * 2011-05-31 2018-10-09 Brandeis University Supramolecular nanofibers and hydrogels based on nucleic acids functionalized with nucleobases
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
RU2627693C2 (ru) 2011-09-14 2017-08-10 СЭМЬЮМЕД, ЭлЭлСи ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/b-КАТЕНИНА
US9187474B2 (en) * 2012-03-07 2015-11-17 Deciphera Pharmaceuticals, Llc Raf inhibitor compounds
UY34781A (es) 2012-05-04 2013-12-31 Novartis Ag Moduladores de la via del complemento y usos de los mismos
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
PL2872157T3 (pl) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
RU2015113746A (ru) 2012-09-27 2016-11-20 Ф. Хоффманн-Ля Рош Аг Замещенные сульфонамиды
MX366429B (es) * 2013-03-15 2019-07-04 Deciphera Pharmaceuticals Llc N-acil-n'-(piridin-2-il) ureas y analogos que presentan actividades anticancerosas y antiproliferativas.
JP6411342B2 (ja) * 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
AU2015223084B2 (en) * 2014-02-25 2019-11-07 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
WO2016205010A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
TWI854164B (zh) * 2016-02-01 2024-09-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物

Also Published As

Publication number Publication date
CO2018008916A2 (es) 2018-08-31
JP6924766B2 (ja) 2021-08-25
DK3411411T3 (da) 2021-06-14
MD3411411T2 (ro) 2021-11-30
AU2017213768A1 (en) 2018-08-09
MX2018008869A (es) 2019-01-30
IL290154A (en) 2022-03-01
IL290154B2 (en) 2023-09-01
RS62187B1 (sr) 2021-08-31
JP2019507130A (ja) 2019-03-14
LT3411411T (lt) 2021-06-25
EP3411411B3 (en) 2022-01-26
ES2882495T3 (es) 2021-12-02
US20190142802A1 (en) 2019-05-16
KR102828456B1 (ko) 2025-07-01
EP3411411A1 (en) 2018-12-12
HRP20210926T1 (hr) 2021-09-03
DK3411411T6 (da) 2022-04-11
IL290154B1 (en) 2023-05-01
JP2021181460A (ja) 2021-11-25
NZ744587A (en) 2025-03-28
MX2022007915A (es) 2022-07-21
EA201891703A1 (ru) 2019-01-31
TWI854164B (zh) 2024-09-01
CN109121414B (zh) 2022-07-05
PH12018501537B1 (en) 2024-01-24
US10849883B2 (en) 2020-12-01
PL3411411T3 (pl) 2021-11-15
US11559515B2 (en) 2023-01-24
TW201733983A (zh) 2017-10-01
CN115490751A (zh) 2022-12-20
TW202222786A (zh) 2022-06-16
IL260545B (en) 2022-03-01
EP3411411A4 (en) 2019-08-28
PT3411411T (pt) 2021-08-06
MY201629A (en) 2024-03-06
NZ784693A (en) 2025-03-28
US20230218578A1 (en) 2023-07-13
MA43979B1 (fr) 2021-06-30
TWI747873B (zh) 2021-12-01
HUE055258T2 (hu) 2021-11-29
CA3011549A1 (en) 2017-08-10
AU2017213768B2 (en) 2023-12-14
SG10202108797UA (en) 2021-09-29
SMT202100494T1 (it) 2021-11-12
ES2882495T7 (es) 2022-04-26
JP7257462B2 (ja) 2023-04-13
WO2017136395A1 (en) 2017-08-10
SG11201805940QA (en) 2018-08-30
PH12018501537A1 (en) 2019-05-15
EP3411411B1 (en) 2021-05-19
US12485109B2 (en) 2025-12-02
CY1124652T1 (el) 2022-07-22
HRP20210926T4 (hr) 2022-03-18
EP3925956B1 (en) 2024-04-10
CN109121414A (zh) 2019-01-01
US20210260035A1 (en) 2021-08-26
PL3411411T6 (pl) 2022-03-14
RS62187B2 (sr) 2022-03-31
KR20180117624A (ko) 2018-10-29
EA039719B1 (ru) 2022-03-03
SI3411411T1 (sl) 2021-07-30
BR112018015289A2 (pt) 2018-12-18
ES2982426T3 (es) 2024-10-16
EP3925956A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR124117A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
AR107694A1 (es) Heteroarilos inhibidores de pad4
AR115646A1 (es) Inhibidores de quinasas dependientes de ciclinas
AR116604A1 (es) Inhibidores de kras g12c
AR088327A1 (es) Agentes inductores de la apoptosis para tratar el cancer y las enfermedades inmunes y autoinmunes
AR103252A1 (es) Compuestos de quinazolina
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR096837A1 (es) Heterociclos tricíclicos como inhibidores de proteínas bet
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR103561A1 (es) Fenilpiridinas herbicidas
AR093308A1 (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
AR088328A1 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cancer y las enfermedades inmunes y autoinmunes
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR107030A1 (es) Inhibidores aza-bencimidazol de pad4
AR117900A1 (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
AR108185A1 (es) Amidas terciarias y método para su uso
AR101479A1 (es) Derivados de 6-alquinil-piridina
AR096041A1 (es) Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg

Legal Events

Date Code Title Description
FB Suspension of granting procedure